

NEW PRODUCT LAUNCH!

Breakthrough in Non-Invasive Lens Autofluorescence Detection


CLEARPATH DS-120™



The CLEARPATH DS-120™ is cleared by FDA as a tool for the measurement of autofluorescence by scanning the crystalline lens of the eye with a blue light.

In independent scientific studies published in peer-reviewed journals, elevated autofluorescence measurements have been linked to high levels of advanced glycosylated end products which accumulate in the presence of diabetes.

Fluorescence vs. Age Prediction Ratio Chart



Observed fluorescence ratios from healthy eyes of 127 healthy subjects, with no cataracts, from Freedom Meditech clinical study.

Follow Us



@FreedomMeditech




Freedom Meditech
Vision for a Healthier Life

Lens Autofluorescence and Diabetes

Human clinical trial designed to confirm efficacy of Lenticular Autofluorescence in identifying diabetic and pre-diabetic candidates (January 2011)

Increasing Fluorescence With Age and the Presence of Diabetes



Substantial Independent Data Supports Correlation between Autofluorescence and Diabetes

- A large number of authors have demonstrated that lens fluorescence is greater in diabetic patients compared to patients without diabetes*
- Many of these authors proposed that this increased lens autofluorescence was due to the irreversible accumulation of Advanced Glycation End-products (AGEs) and served as an index of long-term glycemic control*
- Furthermore, data indicates there is currently on average a seven year lag between the onset and diagnosis of diabetes*
- Fluorescence increases linearly with age in both populations (diabetic and non-diabetic), but was significantly higher in the diabetic population of all ages*

* All citations are from published peer-reviewed scientific and/or medical journals and can be provided upon request.
The uses described in the herein information have not been approved or cleared by the FDA.

Follow Us



@FreedomMeditech

